
Scalp Psoriasis and Biologic Agents: A Review
Author(s) -
Ilias Papadimitriou,
Katerina Bakirtzi,
Alexander Katoulis,
Dimitrios Ioannides
Publication year - 2021
Publication title -
skin appendage disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.773
H-Index - 13
eISSN - 2296-9195
pISSN - 2296-9160
DOI - 10.1159/000517806
Subject(s) - psoriasis , dermatology life quality index , medicine , dermatology , quality of life (healthcare) , scalp , psoriasis area and severity index , plaque psoriasis , erythema , disease , etanercept , rheumatoid arthritis , nursing
Scalp-localized psoriasis is common among patients affected with plaque psoriasis, rendering its treatment exceedingly difficult. Furthermore, the symptoms caused by the disease like scaling, erythema, and pruritus, among others, pose a major psychological impact and a significant regression in the quality of life of the affected patients. Biologics have proved their efficacy in assuaging the symptoms, in terms of Psoriasis Area and Severity Index (PASI) reduction, and offering optimum quality of life, by decreasing the Dermatology Life Quality Index (DLQI) in the patients suffering from plaque psoriasis. Herein, we sought to evaluate the efficacy of biologics and small molecules in controlling the symptoms and their ability to offer long-term maintenance in the disease activity.